TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock Fundamental Analysis

USA • New York Stock Exchange • NYSE:TAK • US8740602052

18.28 USD
+0.18 (+0.99%)
At close: Feb 11, 2026
19.35 USD
+1.07 (+5.85%)
Pre-Market: 2/12/2026, 4:00:00 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

Taking everything into account, TAK scores 5 out of 10 in our fundamental rating. TAK was compared to 191 industry peers in the Pharmaceuticals industry. While TAK has a great profitability rating, there are quite some concerns on its financial health. TAK has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year TAK was profitable.
  • TAK had a positive operating cash flow in the past year.
  • In the past 5 years TAK has always been profitable.
  • Each year in the past 5 years TAK had a positive operating cash flow.
TAK Yearly Net Income VS EBIT VS OCF VS FCFTAK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200B 400B 600B 800B 1T

1.2 Ratios

  • TAK's Return On Assets of 0.73% is fine compared to the rest of the industry. TAK outperforms 78.53% of its industry peers.
  • Looking at the Return On Equity, with a value of 1.48%, TAK belongs to the top of the industry, outperforming 81.15% of the companies in the same industry.
  • The Return On Invested Capital of TAK (2.32%) is better than 79.06% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for TAK is significantly below the industry average of 12.66%.
Industry RankSector Rank
ROA 0.73%
ROE 1.48%
ROIC 2.32%
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.62%
ROIC(5y)2.55%
TAK Yearly ROA, ROE, ROICTAK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2 4 6 8

1.3 Margins

  • TAK's Profit Margin of 2.53% is fine compared to the rest of the industry. TAK outperforms 79.06% of its industry peers.
  • TAK's Profit Margin has improved in the last couple of years.
  • The Operating Margin of TAK (10.76%) is better than 82.72% of its industry peers.
  • TAK's Operating Margin has improved in the last couple of years.
  • The Gross Margin of TAK (65.33%) is better than 74.35% of its industry peers.
  • TAK's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 10.76%
PM (TTM) 2.53%
GM 65.33%
OM growth 3Y-8.47%
OM growth 5Y6.13%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
TAK Yearly Profit, Operating, Gross MarginsTAK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so TAK is still creating some value.
  • The number of shares outstanding for TAK has been increased compared to 1 year ago.
  • TAK has more shares outstanding than it did 5 years ago.
  • TAK has a better debt/assets ratio than last year.
TAK Yearly Shares OutstandingTAK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B
TAK Yearly Total Debt VS Total AssetsTAK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5T 10T 15T

2.2 Solvency

  • TAK has an Altman-Z score of 1.22. This is a bad value and indicates that TAK is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of TAK (1.22) is comparable to the rest of the industry.
  • TAK has a debt to FCF ratio of 6.48. This is a slightly negative value and a sign of low solvency as TAK would need 6.48 years to pay back of all of its debts.
  • The Debt to FCF ratio of TAK (6.48) is better than 82.20% of its industry peers.
  • A Debt/Equity ratio of 0.56 indicates that TAK is somewhat dependend on debt financing.
  • TAK's Debt to Equity ratio of 0.56 is on the low side compared to the rest of the industry. TAK is outperformed by 65.44% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 6.48
Altman-Z 1.22
ROIC/WACC1.41
WACC1.64%
TAK Yearly LT Debt VS Equity VS FCFTAK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2T 4T 6T

2.3 Liquidity

  • A Current Ratio of 1.19 indicates that TAK should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.19, TAK is doing worse than 80.63% of the companies in the same industry.
  • A Quick Ratio of 0.65 indicates that TAK may have some problems paying its short term obligations.
  • TAK has a worse Quick ratio (0.65) than 86.91% of its industry peers.
Industry RankSector Rank
Current Ratio 1.19
Quick Ratio 0.65
TAK Yearly Current Assets VS Current LiabilitesTAK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500B 1T 1.5T 2T 2.5T

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The earnings per share for TAK have decreased strongly by -45.17% in the last year.
  • The Earnings Per Share has been growing by 19.20% on average over the past years. This is quite good.
  • Looking at the last year, TAK shows a decrease in Revenue. The Revenue has decreased by -2.50% in the last year.
  • The Revenue has been growing slightly by 6.84% on average over the past years.
EPS 1Y (TTM)-45.17%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%341.77%
Revenue 1Y (TTM)-2.5%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%4.16%

3.2 Future

  • The Earnings Per Share is expected to grow by 45.21% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, TAK will show a decrease in Revenue. The Revenue will decrease by -0.03% on average per year.
EPS Next Y74.27%
EPS Next 2Y67.89%
EPS Next 3Y45.21%
EPS Next 5YN/A
Revenue Next Year-1.77%
Revenue Next 2Y-0.66%
Revenue Next 3Y-0.03%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
TAK Yearly Revenue VS EstimatesTAK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1T 2T 3T 4T
TAK Yearly EPS VS EstimatesTAK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 50 -50 100

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 79.48, the valuation of TAK can be described as expensive.
  • Based on the Price/Earnings ratio, TAK is valued a bit cheaper than 75.92% of the companies in the same industry.
  • TAK's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.18.
  • A Price/Forward Earnings ratio of 29.16 indicates a quite expensive valuation of TAK.
  • 72.77% of the companies in the same industry are more expensive than TAK, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of TAK to the average of the S&P500 Index (28.01), we can say TAK is valued inline with the index average.
Industry RankSector Rank
PE 79.48
Fwd PE 29.16
TAK Price Earnings VS Forward Price EarningsTAK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, TAK is valued cheaper than 89.01% of the companies in the same industry.
  • 89.53% of the companies in the same industry are more expensive than TAK, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 11.85
EV/EBITDA 10.47
TAK Per share dataTAK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The decent profitability rating of TAK may justify a higher PE ratio.
  • TAK's earnings are expected to grow with 45.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.07
PEG (5Y)4.14
EPS Next 2Y67.89%
EPS Next 3Y45.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 3.58%, TAK has a reasonable but not impressive dividend return.
  • Compared to an average industry Dividend Yield of 0.93, TAK pays a better dividend. On top of this TAK pays more dividend than 95.29% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.80, TAK pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.58%

5.2 History

  • The dividend of TAK has a limited annual growth rate of 1.18%.
  • TAK has been paying a dividend for at least 10 years, so it has a reliable track record.
  • TAK has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)1.18%
Div Incr Years2
Div Non Decr Years3
TAK Yearly Dividends per shareTAK Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2024 2025 2026 50 100 150

5.3 Sustainability

  • TAK pays out 277.04% of its income as dividend. This is not a sustainable payout ratio.
  • The dividend of TAK is growing, but earnings are growing more, so the dividend growth is sustainable.
DP277.04%
EPS Next 2Y67.89%
EPS Next 3Y45.21%
TAK Yearly Income VS Free CF VS DividendTAK Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200B 400B 600B 800B
TAK Dividend Payout.TAK Dividend Payout, showing the Payout Ratio.TAK Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

TAKEDA PHARMACEUTIC-SP ADR

NYSE:TAK (2/11/2026, 8:04:00 PM)

Premarket: 19.35 +1.07 (+5.85%)

18.28

+0.18 (+0.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-30
Earnings (Next)05-13
Inst Owners47.21%
Inst Owner Change-2.16%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap57.75B
Revenue(TTM)4.46T
Net Income(TTM)112.93B
Analysts74.44
Price Target17.61 (-3.67%)
Short Float %0.31%
Short Ratio3.34
Dividend
Industry RankSector Rank
Dividend Yield 3.58%
Yearly Dividend0.61
Dividend Growth(5Y)1.18%
DP277.04%
Div Incr Years2
Div Non Decr Years3
Ex-Date03-30
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.65%
Min EPS beat(2)-121.92%
Max EPS beat(2)90.61%
EPS beat(4)2
Avg EPS beat(4)-2.37%
Min EPS beat(4)-121.92%
Max EPS beat(4)90.61%
EPS beat(8)4
Avg EPS beat(8)-37%
EPS beat(12)6
Avg EPS beat(12)-26.29%
EPS beat(16)8
Avg EPS beat(16)-33.22%
Revenue beat(2)1
Avg Revenue beat(2)-2.91%
Min Revenue beat(2)-6.04%
Max Revenue beat(2)0.21%
Revenue beat(4)1
Avg Revenue beat(4)-3.67%
Min Revenue beat(4)-6.76%
Max Revenue beat(4)0.21%
Revenue beat(8)4
Avg Revenue beat(8)1.91%
Revenue beat(12)7
Avg Revenue beat(12)2.79%
Revenue beat(16)11
Avg Revenue beat(16)3.3%
PT rev (1m)6.62%
PT rev (3m)-0.2%
EPS NQ rev (1m)31.26%
EPS NQ rev (3m)-370.39%
EPS NY rev (1m)-5.03%
EPS NY rev (3m)-17.88%
Revenue NQ rev (1m)0.12%
Revenue NQ rev (3m)2.05%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.55%
Valuation
Industry RankSector Rank
PE 79.48
Fwd PE 29.16
P/S 1.99
P/FCF 11.85
P/OCF 7.46
P/B 1.16
P/tB N/A
EV/EBITDA 10.47
EPS(TTM)0.23
EY1.26%
EPS(NY)0.63
Fwd EY3.43%
FCF(TTM)1.54
FCFY8.44%
OCF(TTM)2.45
OCFY13.4%
SpS9.2
BVpS15.75
TBVpS-3.35
PEG (NY)1.07
PEG (5Y)4.14
Graham Number9.03
Profitability
Industry RankSector Rank
ROA 0.73%
ROE 1.48%
ROCE 3.75%
ROIC 2.32%
ROICexc 2.47%
ROICexgc 10.72%
OM 10.76%
PM (TTM) 2.53%
GM 65.33%
FCFM 16.77%
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.62%
ROIC(5y)2.55%
ROICexc(3y)2.76%
ROICexc(5y)2.73%
ROICexgc(3y)14.61%
ROICexgc(5y)14.15%
ROCE(3y)4.25%
ROCE(5y)4.14%
ROICexgc growth 3Y-6.2%
ROICexgc growth 5Y8.09%
ROICexc growth 3Y-3.88%
ROICexc growth 5Y10.72%
OM growth 3Y-8.47%
OM growth 5Y6.13%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
F-Score5
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 6.48
Debt/EBITDA 3.48
Cap/Depr 58.95%
Cap/Sales 9.86%
Interest Coverage 4.11
Cash Conversion 96.87%
Profit Quality 663%
Current Ratio 1.19
Quick Ratio 0.65
Altman-Z 1.22
F-Score5
WACC1.64%
ROIC/WACC1.41
Cap/Depr(3y)69.03%
Cap/Depr(5y)56.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)9.44%
Profit Quality(3y)309.71%
Profit Quality(5y)308.48%
High Growth Momentum
Growth
EPS 1Y (TTM)-45.17%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%341.77%
EPS Next Y74.27%
EPS Next 2Y67.89%
EPS Next 3Y45.21%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.5%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%4.16%
Revenue Next Year-1.77%
Revenue Next 2Y-0.66%
Revenue Next 3Y-0.03%
Revenue Next 5YN/A
EBIT growth 1Y0.22%
EBIT growth 3Y-0.52%
EBIT growth 5Y13.39%
EBIT Next Year435.35%
EBIT Next 3Y77.31%
EBIT Next 5YN/A
FCF growth 1Y680.23%
FCF growth 3Y-8.86%
FCF growth 5Y9.4%
OCF growth 1Y62.56%
OCF growth 3Y-2%
OCF growth 5Y9.54%

TAKEDA PHARMACEUTIC-SP ADR / TAK FAQ

What is the fundamental rating for TAK stock?

ChartMill assigns a fundamental rating of 5 / 10 to TAK.


What is the valuation status for TAK stock?

ChartMill assigns a valuation rating of 6 / 10 to TAKEDA PHARMACEUTIC-SP ADR (TAK). This can be considered as Fairly Valued.


What is the profitability of TAK stock?

TAKEDA PHARMACEUTIC-SP ADR (TAK) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for TAK stock?

The Price/Earnings (PE) ratio for TAKEDA PHARMACEUTIC-SP ADR (TAK) is 79.48 and the Price/Book (PB) ratio is 1.16.


How financially healthy is TAKEDA PHARMACEUTIC-SP ADR?

The financial health rating of TAKEDA PHARMACEUTIC-SP ADR (TAK) is 3 / 10.